Autoantibodies in vitiligo

Betterle, C.

doi:10.1001/archderm.112.9.1328b

Cited by 17 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study we failed to demonstrate a reactivity against melanin-producing cells in sera from MM patients not only with I IT but also with ICFT which has been shown capable of detecting complement-fixing antibodies in the presence of negative conventional I IT [2,5,11]. In our opinion these results are due to the absence of a specific antibody to melanin-producing cells in the sera studied.…”

Section: Discussioncontrasting

confidence: 73%

Circulating Antibodies in Malignant Melanoma Patients

et al. 1979

Self Cite

View full text Add to dashboard Cite

Sera from 46 patients with malignant melanoma (MM) in different clinical stages and from 25 healthy blood donors were studied by an indirect conventional immunofluorescent technique (IIT) and by an immunofluorescent complement-fixation test (ICFT). No specific and reliable serological reactivity could be demonstrated against autologous and homologous MM and other nonmalignant pigmented tissues. An increased incidence of diffused antinuclear (ANA; 41%) and cytoplasmic epidermal cell autoantibodies (A-CYT; 71%) was observed in the patients by IIT. Statistical evaluation of the results gave significant values in the χ² test in patients for ANA (χ² = 5.2061; p < 0.05) and for A-CYT (χ² = 8.9176; p < 0.01) versus age-matched controls. Thyroid microsomal, gastric parietal cell, smooth muscle and mitochondria autoantibodies were, respectively, detected in 4.3, 4.3, 4.3 and 0% of patients’ sera.

show abstract

Section: Discussioncontrasting

confidence: 73%

Circulating Antibodies in Malignant Melanoma Patients

et al. 1979

Self Cite

View full text Add to dashboard Cite

show abstract

“…[2] The findings of an increased frequency of antithyroid microsomal, antiparietal cell, and antiadrenal antibodies in vitiligo patients support the autoimmune hypothesis. [4,5] The autocytotoxic theory stems from the belief that cytotoxic precursors in melanin synthesis accumulate and this results in cell death. All intermediates in the biosynthesis of melanin are phenols and related compounds.…”

Section: Introductionmentioning

confidence: 99%

Response to Narrow-Band UVB – Vitiligo-Melasma versus Vitiligo

Sharma

Pai²,

Pai³

et al. 2011

American Journal of Clinical Dermatology

View full text Add to dashboard Cite

Patients having both vitiligo and melasma have a significantly better prognosis for repigmentation on the face and limbs with narrow-band UVB compared with patients with vitiligo alone; the vitiligo-melasma patients achieve repigmentation much earlier and also attain a greater level of repigmentation. Unexpectedly, for truncal lesions, patients with vitiligo alone responded better than those with both conditions. Although the vitiligo-melasma group with truncal lesions started repigmenting earlier, the final pigmentation was more extensive in the vitiligo group.

show abstract

“…Vitiligo is considered an autoimmune disease due to the following features: the presence of autoantibodies against melanocytes in patients' sera [3][4][5][6][7], the association of vitiligo with other autoimmune conditions [8][9][10], the presence of organ-specific autoantibodies in the patients' sera [11,12], the detection of autoantibodies in firstdegree relatives of subjects with vitiligo [13], and the association of the disease with HLA-DR4 or HLA-DR1 [14][15][16]. The titres of antibodies against melanocytes in the sera of subjects with vitiligo correlate with the activity and extent of the disease.…”

Section: Introductionmentioning

confidence: 99%

Tyrosinase as an autoantigen in patients with vitiligo

Baharav

Merimski

Shoenfeld

et al. 1996

Clinical and Experimental Immunology

118

View full text Add to dashboard Cite

SUMMARYVitiligo is considered an autoimmune disorder due to the generation and presence of autoantibodies directed against melanocyte antigens in the patients' sera. In the present study we point towards a newly defined autoantigen in vitiligo, the enzyme tyrosinase, which participates in the process of melanogenesis. Anti-tyrosinase antibodies were detected in the sera of seven patients with diffuse and 11 patients with localized vitiligo. Employing solid-phase ELISA to mushroom tyrosinase, we found that patients with diffuse vitiligo had significantly higher titres of IgG anti-tyrosinase autoantibodies than patients with localized disease or healthy subjects. These anti-tyrosinase autoantibodies have relatively high functional affinity to tyrosinase and can be recovered from vitiligo patients' sera by affinity purification. The anti-tyrosinase antibodies do not cross-react with other enzymes recognized as autoantigens in different autoimmune disorders and the autoantibodies do not block the enzymatic activity of tyrosinase, indicating that they are not reacting with the catalytic site of the enzyme. These data point to tyrosinase as an autoantigen in vitiligo and suggest that anti-tyrosinase titres can serve as a marker for disease activity.

show abstract

Autoantibodies in vitiligo

Cited by 17 publications

References 0 publications

Circulating Antibodies in Malignant Melanoma Patients

Circulating Antibodies in Malignant Melanoma Patients

Response to Narrow-Band UVB – Vitiligo-Melasma versus Vitiligo

Tyrosinase as an autoantigen in patients with vitiligo

Contact Info

Product

Resources

About